Overview

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
SU5416 may stop the growth of malignant melanoma by stopping blood flow to the tumor. Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic melanoma that has been previously treated
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Semaxinib